Nanjing Sinolife United Co., Ltd. Class H (3332) AI Stock Analysis

• Market Cap: HK$737.16M
• Dividend Yield: N/A
• Average Volume (3M): 61.53K
• Price to Earnings (P/E): 11.5
• Beta (1Y): -0.36
• Revenue Growth: 30.72%
• EPS Growth: -35.61%
• Country: HK
• Employees: 468
• Sector: Financial
• Sector Strength: 81
• Industry: Household & Personal Products
• EPS (TTM): 0.04
• Shares Outstanding: 946,298,340
• 10 Day Avg. Volume: 57,000
• 30 Day Avg. Volume: 61,533
• PEG Ratio: -0.26
• Price to Book (P/B): 0.91
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.42
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 60 Neutral
• Price Target: HK$0.50 ▲(8.70%Upside)

The stock score is influenced mainly by strong financial performance with notable revenue growth and a stable balance sheet. However, concerns about cash flow management and weak technical indicators are significant risks. The valuation is fair, but the lack of dividend yield is a drawback.

Nanjing Sinolife United Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Nanjing Sinolife United Co., Ltd. Class H (3332) is a company engaged in the production and distribution of health and nutritional supplements. Operating primarily in the health products sector, the company focuses on the development of a variety of dietary supplements, functional foods, and health-related products designed to enhance wellness and address specific health concerns. With a diverse product portfolio, Sinolife serves a wide range of consumer needs through its innovative and quality offerings.

How the Company Makes Money

Nanjing Sinolife United Co., Ltd. generates revenue through the sale of its health and nutritional supplements. The company's key revenue streams include direct sales to consumers, partnerships with retail distributors, and online sales channels. By leveraging its research and development capabilities, Sinolife continuously introduces new products to meet emerging health trends and consumer demands. Additionally, the company capitalizes on strategic partnerships and collaborations to expand its market reach and strengthen its distribution network, contributing significantly to its earnings.

Nanjing Sinolife United Co., Ltd. Class H Financial Statement Overview

Summary

The company exhibits strong revenue growth and improved profitability, underpinned by a robust balance sheet with low leverage. However, the lack of recent cash flow data raises concerns about liquidity and cash management.

Income Statement

The company has shown a significant improvement in gross profit margin from the previous year, rising from 67.34% to 71.95%. Net profit margin also improved from 9.33% to 4.62%, indicating better operational efficiency. Revenue growth rate from 2023 to 2024 was a substantial 32.53%, showing strong sales performance. However, EBIT and EBITDA margins decreased slightly, signaling some pressure on operating profitability.

Balance Sheet

The company maintains a strong equity base with an equity ratio of 77.96%, reflecting stability. The debt-to-equity ratio is low at 0.09, indicating conservative leverage. Return on equity is modest at 8.77%, suggesting room for improvement in generating shareholder returns. Overall, the balance sheet shows stability with low financial risk.

Cash Flow

The cash flow statement shows a concerning lack of operating cash flow in the latest year, which could impact liquidity. Previously, free cash flow showed growth, but the absence of cash flow data for 2024 raises concerns about cash management. Free cash flow to net income and operating cash flow to net income ratios are unavailable, limiting the assessment of cash conversion efficiency.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	747.90M	563.96M	274.85M	252.32M	296.52M
Gross Profit	538.27M	379.66M	160.00M	138.80M	170.70M
EBITDA	48.19M	75.08M	4.88M	-13.49M	-20.96M
Net Income	34.56M	52.60M	-14.25M	-31.71M	-49.60M
Balance Sheet
Total Assets	505.56M	505.42M	436.99M	390.11M	449.73M
Cash, Cash Equivalents and Short-Term Investments	104.53M	122.79M	73.39M	72.06M	77.12M
Total Debt	33.90M	35.16M	35.75M	8.87M	13.46M
Total Liabilities	111.46M	127.35M	113.19M	59.87M	87.37M
Stockholders Equity	394.10M	378.07M	323.80M	330.24M	362.36M
Cash Flow
Free Cash Flow	-6.65M	44.76M	4.05M	-9.68M	3.20M
Operating Cash Flow	957.00K	47.11M	7.92M	421.00K	16.41M
Investing Cash Flow	-6.00M	449.00K	-3.47M	1.52M	-12.49M
Financing Cash Flow	-4.53M	-4.50M	-4.08M	-4.45M	-34.05M

Nanjing Sinolife United Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.46
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3332, the sentiment is Positive. The current price of 0.46 is above the 20-day moving average (MA) of 0.45, above the 50-day MA of 0.45, and below the 200-day MA of 0.57, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.71 is Neutral, neither overbought nor oversold. The STOCH value of 72.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3332.

Nanjing Sinolife United Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3828	74 Outperform	HK$590.36M	4.09	11.13%	17.28%	11.80%	37.53%
2138	66 Neutral	HK$699.27M	19.67	-8.91%	1.69%	169.20%	―
2023	63 Neutral	HK$418.03M	7.52	12.01%	―	25.55%	14.47%
2177	61 Neutral	HK$514.27M	12.52	5.25%	32.26%	-23.89%	―
3332	60 Neutral	HK$737.16M	11.49	8.96%	―	30.72%	-35.61%
Sector *	58 Neutral	$12.52B	5.23	-2.71%	5.27%	5.88%	-56.03%
0157	48 Neutral	HK$1.10B	―	-20.26%	―	5.25%	-581.58%

Nanjing Sinolife United Co., Ltd. Class H Corporate Events

Nanjing Sinolife United Co., Ltd. Enhances Board Governance with New Nomination Committee

Nanjing Sinolife United Co., Ltd. has established a Nomination Committee to enhance its board composition and corporate governance. The committee is tasked with selecting candidates for directors and management, reviewing board structure, and making recommendations on appointments and succession planning, thereby strengthening the company’s strategic direction and operational oversight.

Nanjing Sinolife United Co., Ltd. AGM Resolutions Unanimously Approved

Nanjing Sinolife United Co., Ltd. held its Annual General Meeting on June 6, 2025, where all proposed resolutions were unanimously approved by shareholders. Key resolutions included the approval of the company’s financial reports for 2024, the decision not to distribute profits for that year, and the reappointment of Ernst & Young as auditors. Additionally, a special resolution was passed granting the board a mandate to issue additional H shares, reflecting a strategic move to potentially expand the company’s capital structure.

Nanjing Sinolife United Co., Ltd. Announces 2025 AGM and Key Resolutions

Nanjing Sinolife United Co., Ltd. has announced its upcoming annual general meeting scheduled for June 6, 2025, in Nanjing, China. The meeting will address several key resolutions, including the approval of financial reports for the year 2024, the re-appointment of auditors, and the authorization for the board to manage director and supervisor remuneration. Additionally, a special resolution will be considered to grant the board a mandate to issue new H shares, potentially impacting the company’s capital structure and market operations.